Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

NCT05770882 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
7
Enrollment
INDUSTRY
Sponsor class

Stopped The overall profile does not support development for Hepatocellular Carcinoma

Conditions

Interventions

Sponsor

Great Novel Therapeutics Biotech & Medicals Corporation